Langerhans histiocytosis?

summary

When people's histiocytosis symptoms, it is easy to suffer from Langerhans cell histiocytosis. Langerhans cell histiocytosis is usually accompanied by some symptoms, such as fever, weight loss, ascites, diarrhea, and even liver dysfunction and conductive deafness. If not treated in time, it is easy to suffer from some complications. So here's how to treat Langerhans cell histiocytosis.

Langerhans histiocytosis?

Local therapy: local Langerhans cell histiocytosis place, partial surgical resection, so as to reduce the spread of Langerhans cell histiocytosis. Chemotherapy: in local patients, radiotherapy can be used to treat Langerhans cell histiocytosis. Antibiotic treatment: when the condition is serious, large dose of antibiotic treatment can be carried out. At the same time, physiotherapy can be carried out for a period of time according to the needs, which can reduce the patient's burden.

Patients should keep lying down to avoid the occurrence of bone spur and long bone growth plate injury. It can also be used in adult patients with long bone fracture. Radiotherapy means that for this state of psychotropic drugs, the most commonly used drugs are chlorpromazine and lithium. Both of them are effective in controlling acute symptoms. X-ray examination, examination of pleural effusion. Pleural effusion, pericardial effusion and mild serous thickening could be found on chest X-ray and chest CT, without solid mass or mediastinal enlargement.

If symptoms appear, the most common are dry cough and dyspnea after activity. About 1 / 3 of the patients have systemic symptoms, such as weight loss, fatigue, fever, night sweats and loss of appetite. When patients have systemic symptoms, we should pay attention to check whether they have potential tumor. About 10% of the patients with spontaneous pneumothorax due to rupture of subpleural sac can be the first symptom of the disease.

matters needing attention

The natural course of disease and prognosis of individual differences, about 50% of patients with good prognosis, symptoms and imaging showed partial or complete remission, 30% - 40% of patients with PLCH disease progress gradually, 10% - 20% of patients with progressive severe symptoms, such as recurrent pneumothorax, combined with respiratory failure and pulmonary hypertension. The factors of poor prognosis of PLCH include high age of onset, persistent systemic symptoms, recurrent pneumothorax, extrapulmonary involvement, diffuse cystic changes in the lung, and pulmonary hypertension. The 1-year, 2-year and 5-year survival rates were 63.6%, 57.2% and 53.7% respectively. PLCH recurred in 20% (8 / 29) patients after lung transplantation. Smoking and extrapulmonary involvement may be risk factors for recurrence.